Preservation of topoisomerase genetic sequences during in vivo and in vitro development of high-level resistance to ciprofloxacin in isogenic Stenotrophomonas maltophilia strains

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 1, 2005, Pages 220-223

  Valdezate, Sylvia ^a   Vindel, Ana ^a   Saéz Nieto, Juan Antonio ^a   Baquero, Fernando ^b   Cantón, Rafael ^b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Efflux pump inhibitors; Fluoroquinolone resistance; QRDR

Indexed keywords

ARSENIC TRIOXIDE; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; CIPROFLOXACIN; CLINAFLOXACIN; DNA TOPOISOMERASE; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; SPARFLOXACIN; TROVAFLOXACIN; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; STENOTROPHOMONAS MALTOPHILIA; ADULT; DRUG EFFECT; GENETICS; MICROBIOLOGICAL EXAMINATION;

ADULT; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; STENOTROPHOMONAS MALTOPHILIA;

EID: 24044519069     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki182     Document Type: Article

References (10)

1. Lecso-Bonet M, Pierre J, Sarkis-Karam D [i#et al.#1i] Susceptibility of [i#Xanthomonas maltophilia#1i] to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro. [i#Antimicrob Agents Chemother#1i] 1992; [b#36#1b]: 669-71.
2. Alonso A, Martinez JL. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from [i#Stenotrophomonas maltophilia. Antimicrob Agents Chemother#1i] 2000; [b#44#1b]: 3079-86.
3. Zhang L, Li XZ, Poole K. Multiple antibiotic resistance in [i#Stenotrophomonas maltophilia#1i]: Involvement of a multidrug efflux system. [i#Antimicrob Agents Chemother#1i] 2000; [b#44#1b]: 287-93.
4. Valdezate S, Vindel A, Echeita A [i#et al.#1i] Topoisomerase II and IV quinolone-resistance determining regions in [i#Stenotrophomonas maltophilia#1i] clinical isolates with different levels of quinolone susceptibility. [i#Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 665-71.
5. Doss SA, Tillotson G, Barg S [i#et al.#1i] In-vitro and in-vivo selection of [i#Staphylococcus aureus#1i] mutants resistant to ciprofloxacin. [i#J Antimicrob Chemother#1i] 1995; [b#35#1b]: 95-102.
6. Friedman SM, Lu T, Drlica K. Mutation in the DNA gyrase A Gene of [i#Escherichia coli#1i] that expands the quinolone resistance-determining region. [i#Antimicrob Agents Chemother#1i] 2001; [b#45#1b]: 2378-80.
7. Ribera A, Ruíz J, Jiménez de Anta MT [i#et al.#1i] Effect of an efflux pump inhibitor on the MIC of nalidixic acid for [i#Acinetobacter baumannii#1i] and [i#Stenotrophomonas maltophilia#1i] clinical isolates. [i#J Antimicrob Chemother#1i] 2002; [b#49#1b]: 697-8.
8. Lomovskaya O, Warren MS, Lee A [i#et al.#1i] Identification and characterization of inhibitors of multidrug resistance efflux pumps in [i#Pseudomonas aeruginosa#1i]: Novel agents for combination therapy. [i#Antimicrob Agents Chemother#1i] 2001; [b#45#1b]: 105-16.
9. Sánchez P, Le U, Martinez JL. The efflux pump inhibitor Phe-Arg-beta-naphthylamide does not abolish the activity of the [i#Stenotrophomonas maltophilia#1i] SmeDEF multidrug efflux pump. [i#J Antimicrob Chemother#1i] 2003; [b#51#1b]: 1042-5.
10. Martínez JL, Baquero F. Mutation frequencies and antibiotic resistance. [i#Antimicrob Agents Chemother#1i] 2002; [b#44#1b]: 1771-7.